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ABSTRACT Involvement of the cervical lymph nodes is the
most important prognostic factor for patients with oral/
oropharyngeal squamous cell carcinoma (OSCC), and the
decision of whether to electively treat patients with clinically
negative necks remains a controversial topic. Sentinel node
biopsy (SNB) provides a minimally invasive method for
determining the disease status of the cervical node basin,
without the need for a formal neck dissection. This technique
potentially improves the accuracy of histologic nodal staging
and avoids overtreating three-quarters of this patient popula-
tion, minimizing associated morbidity. The technique has
been validated for patients with OSCC, and larger-scale
studies are in progress to determine its exact role in the
management of this patient population. This document is
designed to outline the current best practice guidelines for the
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provision of SNB in patients with early-stage OSCC, and to
provide a framework for the currently evolving recommen-
dations for its use. Preparation of this guideline was carried out
by a multidisciplinary surgical/nuclear medicine/pathology
expert panel under the joint auspices of the European Asso-
ciation of Nuclear Medicine (EANM) Oncology Committee
and the Sentinel European Node Trial (SENT) Committee.
Keywords Sentinel lymph node biopsy  Carcinomas,
squamous cell  Head and neck neoplasms  Technetium
Tc-99m human serum albumin colloid  Radionuclide
imaging
Abbreviations
SNB Sentinel node biopsy
OSCC Oral/oropharyngeal squamous cell
carcinoma
EANM European Association of Nuclear Medicine
SENT European Sentinel Node Trial group
END Elective neck dissection
SLN Sentinel lymph node
cN0 Clinical node-negative
pN0 Pathological node-negative
cN? Clinical node-positive
pN? Pathological node-positive
Tc-99m Technetium-99
LSG Lymphoscintigraphy
CT Computed tomography
MRI Magnetic resonance imaging
USg-FNAC Ultrasound-guided fine-needle aspiration
cytology
FDG-PET 18F-fluoro-deoxyglucose positron emission
tomography
PET/CT FDG-PET with low-dose CT
MBq Megabecquerel
lGy Microgray
mSv Millisievert
lSv Microsievert
keV Kilo-electron–volt
SPECT Single-photon emission computed
tomography
IV Intravenous
ICRP International Commission on Radiological
Protection
57Co Cobalt-57
153Gd Gadolinium-153
cps Counts per second
QA Uality assurance
QC Quality control
UICC Union Internationale Contre le Cancer
(International Union against Cancer)
H&E Hematoxylin–eosin stain
MM Micrometastasis
ITC Isolated/individual tumor cells
RT-PCR Reverse-transcriptase polymerase chain
reaction
Oral/oropharyngeal squamous cell cancer (OSCC) is one
of the most common cancers worldwide, with more than
274.000 new cases annually.1 Three-quarters of cases affect
people in the developing world, while in developed coun-
tries, OSCC is the eighth most prevalent form of cancer.
Determining the presence or absence of nodal metastasis
is of paramount importance for staging, treatment planning,
and prognosis. The incidence of occult metastases in
patients with clinically node-negative (cN0) OSCC is high,
with many series reporting rates greater than 30%.2–5
Cervical lymph node involvement is the most important
prognostic factor for patients with OSCC.5–7
Elective treatment of the clinically negative neck
remains a controversial topic. Over the last two decades
much work has been undertaken to find reliable predictors
of occult metastases, of which tumor depth appears to be
the best available.8–11 However, the predictive capacity of
tumor depth and other primary tumor characteristics are
still insufficient to negate the need for surgical staging of
the cervical node basin.12,13
Elective neck dissection (END) is the current gold-stan-
dard staging procedure for the cN0 neck, providing valuable
prognostic information regarding nodal status and simulta-
neously treating those patients found to be node positive
(pN?). Previously, ENDs invariably took the form of a
modified radical neck dissection, however there is increas-
ing evidence that selective neck dissection is as efficacious
as comprehensive neck dissection in treating the negative
neck.2,14–20 The shift toward more conservative surgical
procedures has occurred primarily in the last two decades,
facilitated by the work undertaken by Lindberg, Byers, and
Shah to describe the common patterns of lymphatic drain-
age.3,21,22 Knowledge of these patterns has allowed the
extent of neck dissections to be progressively limited to
those nodal levels at highest risk, and sentinel node biopsy
(SNB) represents an extension of this philosophy.
The aim of this review is to provide an evidence-based
guideline for the use of sentinel node biopsy as a staging
tool for patients with early OSCC, presenting the best
available evidence at the time of writing.
The existing literature was reviewed, utilizing electronic
techniques (Medline, Best Evidence, the Cochrane Library,
Dare) and hand-searching techniques. Where little or no
data existed from randomized controlled prospective trials,
emphasis was given to data from large series or reports
from recognized experts in the field. It is recognized that
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higher-level evidence from future studies may modify the
recommendations made in this manuscript.
DEFINITION OF A SENTINEL NODE
The sentinel node concept states that the spread of a
tumor is embolic in nature, via the lymphatics to the first-
echelon lymph node(s) encountered in the regional draining
basin. These represent the lymph nodes most likely to
harbor occult metastases, and are designated the sentinel
lymph nodes (SLNs). Excisional biopsy and pathological
evaluation of the SLNs therefore allows for prediction of
the disease status of the remaining cervical lymph node
basin, potentially avoiding the need for a neck dissection.
Sentinel lymph nodes need not be those closest to the tumor,
and there may be multiple SLNs.23 With the application of
early dynamic lymphoscintigraphy, lymphatic channels are
usually visualized, and nodes on a direct drainage pathway
may be distinguished. The practical approach may include
the combination of available detection techniques.
Lymphatic mapping and sentinel node biopsy (SNB)
were first reported in 1977 by Cabanas for penile cancer.24
In 1992, Morton and colleagues first described the use of
intradermal isosulfan blue dye injection for lymphatic
mapping and SLN localization in patients with malignant
melanoma.23 The following year, Alex et al. described a
peritumoral intradermal injection of radioactive tracer (99m
technetium sulfur colloid), followed by imaging and intra-
operative gamma probe radiolocalization of SLNs.25 The
sentinel node concept has since been extensively studied
and validated for patients with cutaneous melanoma and
breast cancer.26,27 Studies to date have also indicated a high
level of accuracy in patients with OSCC.28,29
CLINICAL INDICATIONS
Inclusion Criteria
The most important inclusion criterion for SNB is a
clinically negative neck, as defined by physical examination
and clinical imaging by computed tomography (CT), con-
trast-enhanced magnetic resonance imaging (MRI),
ultrasound-guided fine-needle aspiration cytology (USg-
FNAC), and/or 18F-fluoro-deoxyglucose (FDG) positron
emission tomography (PET) with or without low-dose CT
(PET/CT).30,31 There remains considerable debate on the
preferred imaging modality, and to date none have the ability
to detect small or micrometastatic tumor deposits, but all
techniques improve on the sensitivity of palpation alone and
are therefore recommended prior to SNB. Recently, the high
specificity of PET has been highlighted as an important
means of avoiding unnecessary neck dissections.30 Gross
lymphatic involvement can lead to distortion of the normal
architecture, leading to aberrant drainage patterns and biopsy
of false sentinel nodes.32 SNB is therefore contraindicated to
stage clinically positive necks.
Following the first report of SNB for OSCC, the technique
has undergone extensive validation against the gold-stan-
dard END, for tumors located in the oral cavity and
accessible subsites of the oropharynx.29,33,34 It has been
demonstrated to be an accurate means of staging the clini-
cally negative neck, and more recently the potential
prognostic value of SNB for these tumor sites has also been
highlighted.35 While SNB has been successfully reported for
tumors in other locations such as the hypopharynx and
supraglottic larynx, there remain significant technical bar-
riers, and SNB for these sites should therefore still be
considered investigational.36 Poor access to these sites
requires general anesthesia and endoscopic guidance for
radiotracer injection, precluding the use of preoperative
lymphoscintigraphy (LSG), while the close proximity of the
primary tumor to the first-echelon lymph nodes can poten-
tially obscure the true location of SLNs. Additionally,
advanced stage at presentation is common for these hidden
tumors, precluding the use of SNB or indeed any surgical
intervention.
There is an existing consensus that SNB for OSCC
should be restricted to early tumors staged T1/2.37–39
Larger tumors are difficult to completely surround with the
tracer injection, tend to drain to multiple lymphatic basins,
and in most patients require a neck dissection for access to
the primary tumor or defect reconstruction. Inclusion of
T3/T4 tumors in study protocols can lead to variability in
the accuracy of the technique.37
The first and most frequent indication for SNB is to
stage the ipsilateral cN0 neck in patients with a unilateral
primary tumor. A second indication is for assessment of
bilateral cN0 necks in primary tumors close to, or crossing,
the midline. The third indication is for assessment of the
contralateral cN0 neck in primary tumors close to the
midline with an ipsilateral cN? neck, in order to decide
whether these patients need bilateral neck dissections, or an
ipsilateral neck dissection and contralateral SNB only.
Patients should also be fit enough preoperatively to with-
stand a neck dissection.
Patients who have received prior radiation or surgical
treatment to the neck are routinely excluded from SNB
protocols, since the previous intervention can distort the
normal lymphatic pathways and give rise to unexpected
patterns of metastasis. It is possible that lymphatic mapping
and SNB may yield potentially useful information in these
patients. Similarly, patients with small recurrent or second
primary tumors may also benefit from lymphatic mapping
to guide surgical intervention. However, these applications
of the SNB technique, whilst clinically attractive, remain
largely unexplored.
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Exclusion Criteria
In pregnant women, the urgency and the necessity of
staging the neck should be discussed. Lymphoscintigraphy
is specifically contraindicated in the pelvis of pregnant
women, but no such recommendations are currently avail-
able for the head and neck. As discussed in the ‘‘Dosimetry’’
section, the risk of fetal damage is negligible during routine
SNB procedures. However, SNB protocols should be
modified in pregnant patients to minimize risks of radiation
exposure and blue-dye injections. For example, the use of a
1-day protocol allows a lower injected radiation dose, and
the additional radiation associated with SPECT/CT imaging
may not be warranted in the pregnant patient. SNB can be
performed in lactating women, but it is advised that
breastfeeding be discontinued following the proce-
dure. OSCC is rare in children, though each case should be
treated individually. In the UK, Nanocolloid is approved for
use in children, though licencing varies between countries.
The potential benefits of sentinel node biopsy are not as well
delineated in the pediatric population and, in practice, most
SNB trial protocols generally exclude these patients from
participation. Off-label use of radiopharmaceuticals should
be considered with caution and with respect to an individual
risk–benefit analysis. Other relative contraindications
include known allergy to albumin colloid, and primary
tumor treatment by external-beam radiotherapy.
In summary, SNB is currently indicated for cT1/2, cN0
oral, and select oropharyngeal SCC, where it may be
considered a valid alternative to elective neck dissection.
Other head and neck sites, histologies, and clinical situa-
tions remain under investigation.
RADIOPHARMACEUTICALS
Introduction
A variety of colloidal and soluble tracers have been used
over the years for lymph studies. It is believed that radio-
colloids are taken up by macrophages in lymph nodes
whereas the transit of macromolecules through lymph nodes
is delayed simply because of their large molecular size.40
Choice of Radiopharmaceutical
The main radiopharmaceutical used in European studies
of sentinel node localization in oral cancers is Tc-99m-
labeled human serum albumin colloid (Nanocoll) (GE
Healthcare). Nanocoll has a particle size range of 5–
80 nm, with a reported mean size of 8–30 nm.40 Although
in theory a larger particle such as Albures (GE Health-
care) or Sentiscint (Medi-Radiopharma) may be preferred
for tumors in the floor of mouth or anterior tongue where
lymphatic densities are high, Nanocoll performs satis-
factorily in all tumor types studied.37 Nanocoll migrates
to the sentinel node within minutes, yet prolonged retention
allows surgery to take place the following day.
Other radiocolloids which have been used include Tc-
99 m rhenium sulfide colloid (Nanocis, IBA), which has
been shown to have a mean particle size of 23–25 nm.41
Tc-99 m sulfide colloid has also been used. Standard
preparations of Tc-99 m sulfide colloid result in a wide
range of particle sizes, so the product is often filtered
through a 100- or 200-nm membrane filter to obtain a
smaller and more uniform size distribution. While there are
currently no clinical studies comparing different radio-
pharmaceuticals, investigators have described satisfactory
results with each of the available colloids.42,43
Preparation and Quality Control
Nanocoll is labeled by incubation with Tc-99 m
pertechnetate at room temperature for 30 min.44 Radio-
chemical purity can be checked by thin-layer chroma-
tography, and labeling efficiency should be [95%. The
EANM guidelines on current good radiopharmacy practice
(cGRPP, www.eanm.org) recommend that labeling effi-
ciency be checked on each preparation. The stated expiry is
6 h after preparation, although extended stability has been
demonstrated.45
Drug Interactions and Adverse Effects
No interactions of drugs with radiocolloids are expected
following local intradermal or subcutaneous application.
Adverse effects are rare and mild following interstitial
application of radiocolloids, although allergic reactions
have been reported with Nanocoll and the blue dyes used at
surgery.46–48 The incidence of allergic reactions is too low
to quantify, but appropriate emergency medicines should
be kept available during the procedure.
Summary
Tc-99 m-labeled Nanocoll is easy to prepare and
supply, and has suitable properties for sentinel node
localization in oral cancers, with rapid migration to the
sentinel node and prolonged retention.
DOSIMETRY: PATIENT
General Remarks
Presently available dosimetric data are derived from the
breast cancer SNB literature, where the absorbed doses to
patients are determined to be low; therefore, the radiation risk
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associated with this procedure is low. While no specific OSCC
data exist, the radiopharmaceuticals and administered activity
are identical, leading to the assumption that OSCC SNB is a
safe procedure from the radiation protection point of view.
Patient Exposure
The estimated local radiation dose varies greatly,
depending on the administered dose and time to surgery.
As mentioned in the ‘‘Injection’’ section, there is little
consensus on the optimal administered dose and timing of
surgery relative to the radiocolloid injection. Most centers
perform LSG within 24 h of surgery, but recommendations
for administered activity range from 15 MBq (for a same-
day procedure) to 120 MBq (for a 2-day procedure) in a
total injection volume of 0.4–1.0 ml. The aim is to achieve
an activity of at least 10 MBq at the time of surgery.49,50
Current EANM guidelines for SNB in breast cancer report
a mean value for the effective dose of 0.048 mSv.51 While
other authors have reported doses approximately tenfold
higher, these remain low compared with other nuclear
medicine procedures.52 Extensive calculations performed
by the Memorial Sloan–Kettering Cancer Center have
confirmed the safety of SNB by reporting an effective dose
around 0.2 mSv.53
Fetal Exposure
The maximum value for fetal absorbed dose has been
calculated to be 0.013 mSv following injection of
18.5 MBq.53 This dose is equivalent to that received by the
mother from 1 day of natural background radiation in the
USA, and is orders of magnitude below the 100–200-mSv
threshold for deterministic effects (malformation, growth
retardation, neurodevelopmental abnormalities).52,54 Cur-
rent consensus is that noncancer health effects are not
detectable below 50 mSv, while congenital malformations
occur above 200 mSv.53 With respect to childhood cancer
induction (stochastic effect), the International Commission
on Radiological Protection (ICRP) reports a threshold of
10 mSv for a 40% risk increase.54
In summary, the advantages of SNB for OSCC outweigh
the potential risks of the absorbed radiation dose, and this
is also true for pregnant patients. While SNB is not con-
traindicated in pregnant patients, it is preferable to use a
same-day protocol, enabling a lower injected dose.50
Lactating Women
The current recommendation is that nursing mothers
should suspend breast-feeding for 24 h following radiophar-
maceutical injection, during which time the general anesthetic
agent and radiocolloid will be excreted in breast milk.51
DOSIMETRY: STAFF
Staff in Operating Room
Studies in breast and melanoma patients have determined
the mean whole-body dose received by surgical staff to be
\1 lSv per operation, with the maximum dose to the sur-
geon of \2 lSv.52,55–57 The absorbed doses are further
minimized when SNB is performed at 24 h after injection.58
Monitoring of operating room personnel for occupational
exposure during the procedure is therefore unnecessary, and
additional shielding is not required. While the pregnant
surgeon or scrub nurse requires specific consideration,
participation in fewer than 100 SNB operations during the
gestation will remain below the recommended radiation
exposure limits for pregnant women.57
Staff in Pathology Department
Radiation exposure to pathology staff is very low, and
should not require badge monitoring. Even personnel per-
forming unusually high numbers of procedures receive
radiation doses well below established limits for members
of the general public.59
Radiation Safety Precautions
Labeling specimens as radioactive for transportation to
the laboratory is not required, since the surface dose rate is
\5 lGy/h.60
Radioactive Clinical Waste
Surgical instruments and pathology slides appear to stay
at background radiation levels, while measurable contam-
ination of absorptive surgical sponges and other materials
used in proximity to the injection site is observed.61 It is
advisable to monitor these materials for contamination, and
contaminated materials should be held for an appropriate
period of decay in storage before disposal.52,59
INJECTION
The lymphatic anatomy within the oral cavity and oro-
pharynx is extremely complicated and varies significantly
between subsites, emphasizing the need for precise injec-
tion technique.39,62,63
Patient Preparation
No special preparation is needed. Patients should be
fully informed about the procedure, including discussion of
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potential problems such as bleeding and discomfort, before
consent can be obtained.
Syringe, Activity, and Volume
Tuberculin syringes with minimal dead space are rec-
ommended; otherwise 0.1 mL air may be drawn into the
syringe behind the radiocolloid to ensure complete
administration. A 25- or 27-gauge needle should be used.
The total activity to be injected may vary, depending on the
size and location of the primary tumor. As described in the
‘‘Dosimetry’’ section, there is currently little consensus on
the optimum activity for injection, and this varies consid-
erably from 15 to 120 MBq between studies.39,64,65 The
total injected activity should be adjusted according to the
timing of LSG with respect to surgery. Higher doses are
required for a 2-day protocol, in order to ensure that the
activity exceeds 10 MBq at the time of surgery.50 Small
volumes of 0.1–0.2 mL per aliquot are recommended to
minimize contamination due to the resistance of tongue
tissue. Contamination can be avoided by placement of a
sheet over the injected region and a gauze swab over the
needle puncture site before withdrawal. Following injec-
tion, the skin/mucosa should be checked for contamination.
Injection Site and Depth, and Number of Injections
Tracer should be injected at 0.1–0.5 cm from the tumor
or scar margin. The number of aliquots to be injected varies
(two to four) according to the size and location of the
lesion. The tracer should be administered on each side of
the tumor/scar, keeping as a reference the orientation of the
surgical scar. For lesions in sites with abundant soft tissue
(i.e., soft palate or floor of the mouth) four separate sub-
mucosal injections must be given around the lesion (at 3, 6,
9, and 12 o’clock). For lesions located in muscle (i.e.,
tongue), injections should be performed according to the
depth of the lesion. Ideally, the operating surgeon should
be present for the injections to ensure consistency with
injection of blue dye if used. Following injection, bleeding
may be controlled with a gauze swab, and the patient
should be asked to use a mouth rinse to minimize pooling
of the radiotracer in the oral cavity.34
IMAGING
Introduction
Lymphoscintigraphy uses a gamma camera to assess the
drainage of injected radiotracer via the lymphatic capil-
laries to the larger collector lymphatics until it either passes
through, or is retained within, the regional lymph nodes.66
Accurate preoperative localization and cutaneous marking
of the SLNs correlates well with the precision of the sur-
gical procedure.67,68
Cameras and Camera Settings (Quality Control)
A large-field-of-view gamma camera equipped with a
high- or ultrahigh-resolution low-energy collimator should
be used, with a 10–20% window centered on the 140-keV
energy peak of Tc-99 m. A two-headed camera allows
simultaneous dynamic acquisition in the anterior and a
lateral projection, and saves time for the static images and
SPECT.69 Quality control for the gamma camera should be
routinely performed and should follow published
protocols.70
Image Acquisition
Dynamic acquisition for 20–30 min (20 s per frame)
with a 128 9 128 matrix or 256 9 256 matrix starting
immediately after radiotracer injection will show the
drainage pattern and help to differentiate between sentinel
nodes, which can appear very early following injection,
and second-echelon lymph nodes.69,71 Two (or three if a
three-headed camera is used) simultaneous images in the
anterior and lateral projections are recommended.
Static images in the anterior and lateral projections from
one or both sides (and oblique as needed) are acquired
(300 s, with a 256 9 256 matrix) to localize the nodes in
three dimensions. If hot nodes are not clearly depicted,
static images can be repeated at, e.g., 2 h, 4–6 h or even
just before surgery. The patient is imaged in the supine
position with head up. A small flat pillow under the neck
may help to fixate the head and neck area.
SPECT imaging may improve the identification of
SLNs, especially close to the injection site. Lesion
detectability is increased by attenuation and scatter cor-
rection, which is easily accomplished with hybrid SPECT/
CT devices.69,72 The increased anatomical detail provided
with CT improves localization of SLNs to the anatomical
neck level.69 SPECT acquisition parameters can be 128 9
128 matrix, 180 in the anterior L-mode rotation, 3 angle
step, with 20–25 s per projection or 60 steps per head, 30 s
each, with slice thickness of 4.42 mm.69,73
CT acquisition parameters differ depending on the CT
system used. To date, most reports on SPECT/CT for SNB
in oral cancer have used a slow, low-end CT scanner (GE
Hawkeye) with acquisition performed over 220 using 16 s
for each transaxial slice, with a fixed tube current of
2.5 mA, 140 kV, and slice thickness of 10 mm.69,73 With
fast, high-end CT scanners providing higher-quality CT
scans, either a low dose or a higher dose of CT can be used.
Low-dose parameters can be, e.g., 20 ms per slice, slice
thickness/increment 3/3 mm, and 120 kV. If a diagnostic
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CT scan is required, IV contrast can also be used. If CT
images are used for attenuation correction, inspection of
both uncorrected and attenuation-corrected SPECT images
is recommended, to avoid overlooking contrast-induced
artifacts on the latter.
A number of studies have reported advantages of adding
SPECT/CT to planar imaging, including identification of
missed SLNs, exclusion of ambiguous SLNs, and/or better
anatomical localization in 30–47% of patients.69,73 How-
ever, it has been suggested that meticulous oblique planar
imaging can visualize the additional SLNs seen with
SPECT imaging, and this may represent an adequate
alternative.74 Furthermore, a number of investigators have
reported no advantage to SPECT imaging with respect to
the number and location of visualized hotspots.75,76 The
true role of SPECT imaging for OSCC SNB has yet to be
determined. If used, SPECT/CT should not be a substitute
for meticulous planar imaging technique.
The location of SLNs harvested during surgery does not
always correlate perfectly with the preoperative imaging,
though higher-quality CT images can allow visualization of
individual SLNs \1 cm, leading to improved preoperative
and intraoperative SLN localization.69,77
Body Contouring
To facilitate topographic localization, a 57Co flood
source (or, if available, a 153Gd source) can be used for
simultaneous transmission imaging in each projection.
Since there is a risk of missing faint nodes when using a
transmission source, it has been suggested to repeat the
scan without a transmission source.78 Alternatively, a
radioactive point source may be used to outline the
patient’s contour while recording the scan.
Image Interpretation
On dynamic imaging, SLNs are identified as one or
more foci to which lymphatic drainage passes, and may be
multiple, in one or several areas of the neck, ipsilateral and/
or contralateral to the primary tumor.79 Imaging should
begin immediately, since SLNs can be seen in the first
minute after injection.80 Foci appearing only on later
images are also labeled as SLNs, and most appear within
1–3 h.74,81
According to some reports, SPECT/CT may identify a
median of one additional SLN compared with planar
imaging. In addition, SLNs located very close to the pri-
mary tumor may be detected by SPECT/CT but not with
the gamma probe during surgery.69 While the benefits of
SPECT/CT have not been universally accepted, both planar
and SPECT images demonstrate good or excellent
inter- and intraobserver agreement for evaluation of SLNs,
with kappa values of 68–89%.74–76
Nonvisualization
SLNs are usually detected between 15 and 60 min after
radiotracer injection. Failure to detect SLNs may be related
to incorrect injection technique or close proximity of SLNs
to the injection site (e.g., floor of mouth tumors). In addi-
tion, metastatic deposits may block lymphatic drainage,
causing nonvisualization of SLNs.32,82 Repeat injection
and imaging may be considered, however proceeding to
neck dissection is preferred in order to avoid a false-neg-
ative SLN.
Aberrant Nodes and In-Transit Sentinel Nodes
Individual lymphatic mapping by lymphoscintigraphy is
a major advantage of SNB, demonstrating occasional
unexpected drainage to, e.g., level IV or contralateral
metastases from well-lateralized tumors.64,74,82–90 In addi-
tion, LSG has been reported to detect ‘‘in-transit’’ lymph
nodes: SLNs lying between the primary tumor and the
regional lymph basin.91 These have been described in the
context of malignant melanoma, but to date there have
been no reports of in-transit SLNs in OSCC.
REPORT AND DISPLAY
Introduction
There are two main indications for careful report and
display of the results from lymphoscintigraphy:
(1) unambiguous guidance for surgical biopsy, and (2) a
comprehensive dataset for ongoing/future studies.37,74
Report
The type of radiocolloid, lot number, volume injected,
and effective dose should be recorded, along with the ini-
tials and title of the nuclear medicine physician or surgeon
performing the injection. The type of camera used and
imaging technique should be described in detail:69
1. Start time for dynamic imaging;
2. Timing and location of the first-echelon node(s) that
appear;
3. Timing and number of anterior, posterior, and oblique
recordings;
4. Timing and location of any additional (second-eche-
lon) nodes; these should be clearly differentiated from
the first-echelon nodes;
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5. If CT or hybrid imaging is used, the manufacturer,
software, and protocol should be described in detail.
The number and location of nodes recorded by these
modalities should be described and compared with
planar recordings. It should be clearly stated if the
results of the tomographic images differ from the
planar recordings.
Shine-through from the primary tumor or opposite side
should be described and marked clearly on the images.
Increased absorption in the thyroid gland can be seen due
to unstable colloid solution as a result of a colloid pro-
duction error, and this may lead to difficulties in
interpreting the lymphoscintigraphic images.92 Artifacts
may also occur due to cutaneous contamination at the time
of injection.93 Rarely, a widened lymphatic capillary may
form a ‘‘colloid lake;’’ however, the associated hotspot will
invariably disappear during subsequent imaging, in con-
trast with true SLNs.
Display
Lymphoscintigraphic findings should be summarized by
the nuclear medicine physician, providing a clear, unam-
biguous report for preoperative consultation. In addition,
hardcopy or digital copies of the LSG images should be
available to the surgeon, both prior to and during
surgery.37,74
Skin Marking
First-echelon nodes should be marked on the skin using
one color of indelible marker, guided by gamma camera
and handheld gamma probe.94 Second-echelon nodes
should be marked with a different color, and clearly
differentiated.
USE OF DYE
Introduction
The use of blue dye in head and neck mucosal cancer
sentinel node surgery is optional. However, when used it is
a useful adjunct to aid SLN localization and harvest. Blue
dye cannot be used alone to perform OSCC SNB, but can
be used in addition to radiolocalization with preoperative
LSG and intraoperative gamma probe use.34
Following injection, blue dye drains to the SLNs via the
same lymphatic pathways as radiocolloid, staining the
channels, which can then be followed to the first-echelon
nodes. Direct visualization and dissection of these channels
is a natural process for the head and neck surgeon.
Rarely, nonradioactive blue nodes may contain metas-
tases in the absence of a tumor-positive radioactive node;
two such SLNs were reported in a series of 40 patients
undergoing SNB with both radiocolloid and blue dye
injection.63 The handheld gamma probe is more sensitive
for the detection of sentinel nodes, and not all radioactive
nodes will also appear blue.28 However, blue dye may aid
the surgeon perform SNB, both for technical success of the
procedure and for identification of subclinical nodal
metastasis.
Contraindications and Special Precautions
Blue dye is contraindicated in children, pregnant
women, lactating women, and those who have a history of
allergy to the blue dye or any of its ingredients. It can,
however, be used in all mucosal sentinel node procedures,
for any malignant process for which the procedure has been
deemed suitable, including OSCC.
Blue Dyes
In the UK and Europe, the blue dye used is Patent Blue
V (Laboratoire Guerbet, Aulnay-Sous-Bois, France; Fig. 1)
which comes in 2-ml vials at 2.5% concentration. Outside
of Europe, the use of other agents such as Isosulfan Blue
(Lymphazurin TM) is more common. Gloves should be
worn to avoid staining, and a gauze swab used to prevent
dye spillage where possible. The dye will rarely mask the
edge of the tumor and, if this is a concern, the tumor edge
can be marked prior to injection with staples or diathermy
marks.
FIG. 1 Patent Blue V dye
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TIMING OF INJECTION
Patent Blue V dye is injected at the time of surgery, under
general anesthetic. It takes approximately 10–15 min for a
significant amount of dye to travel from the injection site to
the sentinel node and this is the approximate time it takes to
scrub, prepare the patient, make the initial excision, and
begin to explore the neck. The patient and anesthetist should
be informed that the dye will be excreted in the urine, and the
urine will remain discolored for approximately 2 days.
INJECTION TECHNIQUE
One vial of dye is injected slowly into the tissues sur-
rounding and deep to the tumor, to minimize leakage from
ulcerated tumors. Gauze swabs may be used to protect
normal tissue and mop up excess dye. The number of
injections is usually between two and four, but is as many
as is necessary to completely surround the tumor on its
deep and lateral surfaces. Occasionally it may be necessary
to grab the tongue with forceps or a retracting suture during
the injection. The injection site should not be massaged, in
order to maintain oncologic safety of the procedure.
Adverse Effects
Anaphylaxis and allergic reactions, while rare, are a
possibility, and clinicians should be mindful of this during
the injection.95 In the event of a reaction, the injection
should be discontinued and appropriate resuscitation per-
formed. A decision should be made as to whether to
continue or abandon the procedure based on clinical find-
ings and discussion between the surgeon and anesthetist.
The mucosa is stained after injection, however the dye
tends not to diffuse more than the margins of excision of
the tumor and it has not been the authors’ (T.S.) experience
that dye interferes with pulse oximetry or pathologic
interpretation of the excised tumor specimen.34
In summary, injection of blue dye is a useful adjunct to
gamma probe localization of the sentinel node. It is an
optional procedure, but one that offers significant advan-
tages for OSCC SNB.
GAMMA PROBE
Introduction
There are a wide variety of gamma probes available
with individual feature sets, each requiring specific training
and information. In many countries, effective competency
training is required as part of the regulations governing the
use of radioactivity.
Probe Components
The gamma probe is a radiation detector, providing a
count rate from gamma rays. The handheld probe contains
the radiation detector, either a crystal or a solid-state
device, with surrounding metal shielding and collimation to
give a restricted field of view (Fig. 2). It is connected to a
power supply and an analyzer unit which receives electrical
signals from the radiation detector. The analyzer and
handheld probe together form the probe system, which may
be powered by mains connection or battery. The analyzer
provides a response related to the detected count rate,
usually by audible pitch or volume variation and by a
visual display as a dial or digital count rate (counts per
second, cps). The probe technology is described in a
number of reference books.96–98
Probe Size and Shape
Probes typically have outer dimensions of 12–15 mm,
with smaller probes producing problems related to the
smaller—less sensitive—detector, and less adequate
shielding of the probe housing from gamma rays. Probe
tips may be angled relative to the handle. This may be
viewed as an advantage for minimal-access surgery, or a
disadvantage due to surgeon preference.
Probe Performance
Probe performance is described in terms of its spatial
resolution and its count sensitivity.99–101 Spatial resolution
indicates how spread out the signal is from a point source;
FIG. 2 Components of the gamma probe
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sensitivity is the number of cps for a given strength of
source. At a typical node depth of 30 mm, a point-source
node will appear to be about 25 mm wide due to the
imperfect spatial resolution of the probe, and resolution
worsens with increasing distance. Many nodes contain well
below 1% of the injected activity, and with a 6 h half-life
of Tc-99 m the activity in a given node can be low, par-
ticularly if the surgery is delayed after injection of the
radiopharmaceutical. A probe should be able to achieve
sensitivity in the range 650–900 cps/MBq of Tc-99 m for a
3-cm-deep node. For a 3-cm-deep node with 1% uptake
from a 40 MBq injection of radiocolloid, with surgery at
2 h after injection, the surgeon will see a count rate of
about 220 cps. The detected count rate falls rapidly with
deeper nodes, and if this arises with lower percentage
uptake and longer delay from surgery there may be a much
lower count rate and more difficult localization. With
experience, localization at low count rates is possible, but
with greater variability, longer search time, and less con-
fidence than at higher count rates.
The probe also picks up counts from sources that are not
directly in front of the probe; gamma rays can penetrate
through the side of the probe, and scattered gamma rays
can enter the detector. Adequate shielding of the probe is
therefore important, especially for OSCC due to close
proximity of the injection site. The rejection of scatter is
achieved by having a probe with a good ‘‘energy resolu-
tion,’’ and with a narrow window.
Probe Controls
The probe analyzer has a number of settings affecting
practical performance of the probe, and therefore ease of
SLN localization. These include:
Energy Window Setting For Tc-99 m, the probe should
be set to a fixed energy level of 140 keV, but the ‘‘width’’
setting is variable. The wider the window, the higher the
sensitivity, but the greater the scatter detected. This is
especially problematic close to the injection site, and the
‘‘high-sensitivity’’ (wider window) setting is therefore most
useful for low-uptake nodes remote from the injection site.
Collimation Collimators may be removable, allowing
great gain in sensitivity while sacrificing spatial resolution.
Removal of the collimation can aid localization of low-
uptake nodes remote from the injection site.
Additional Shielding Direct penetration of gamma rays
through the side of the probe may be reduced by the use of
lead plates to shield the injection site.
Integration Time Some systems allow averaging of the
signal over time, reducing signal variability. Integration
times [1 s must be used with caution, since the user may
be misled by the delay between the probe position and the
corresponding sound signal.
Count Range The probe produces an audible change in
pitch between a minimum and maximum cps range, e.g.,
100–1000 cps. Counts outside the set range will all produce
the same (low or high) pitch, necessitating adjustment.
Inappropriate range setting can lead to failure of
localization. Some probe systems can automatically
adjust the pitch range for the detected counts, though this
can be confusing when trying to get a sense of the absolute
count at any point.
Care of the Probe and Quality Assurance
All radiation detectors must be checked and managed
within a quality assurance (QA) program. Surgeons are
advised to work closely with their nuclear medicine col-
leagues and medical physicists in setting up quality control
(QC) procedures. Recommendations for testing are:
• On purchase, tests of performance are advised to give a
reference value for sensitivity, energy resolution, and
spatial resolution, and to form a baseline for day-to-day
checks;
• Before each use, a basic check of function and
performance with determination of count rate sensitiv-
ity to a long-lived radioactive source and its energy
spectrum;
• Visual inspection for damage, particularly cables and
connectors. All users must be advised that the probe
detector is easily damaged by dropping;
• In the operating room, aiming the probe at the
injection site can demonstrate that the probe is
functioning; however, this is not a substitute for QC
checks since even a 50% loss in sensitivity would not
have any effect on the general response to the
injection site.
Sterility
The probe is placed into a sterile sheath, though this
makes the probe tip larger. The skin surface may be
scanned before sheathing, in which case the probe must be
decontaminated by wiping with 70% alcohol or other
supplier-recommended agent. When removing a sheath,
care must be taken not to accidentally take off any
removable collimator, since these are costly to replace.
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Common Sources of Error or Problems
1. Dropping the probe will usually cause it to stop
functioning, so staff should be made aware of its fra-
gility, and QA performed before each operating list. A
spare probe can easily be interchanged. Damage to the
cable and connectors are avoided by careful handling,
aided by staff training.
2. Failure to replace a removable collimator considerably
reduces spatial resolution.
3. Incorrect energy window setting may be caused by
selecting the wrong isotope, or if the QA procedures
are performed with a Co57 isotope and the procedure
specifies that the energy window is set to Co57. To
avoid this, perform all QA procedures on the Tc-99 m
window, unless the window is unusually narrow, in
which case attention must be paid to resetting the
window after QA.
4. Good support from radiation experts in the nuclear
medicine or medical physics department can be
invaluable, particularly for routine QA, optimization,
and purchase advice on performance. Awareness of the
major pitfalls, both technical and patient-related vari-
ations, is essential.
SURGICAL TECHNIQUE AND GAMMA PROBE
DETECTION
The following remarks are valid provided that (a) pre-
operative lymphoscintigraphy is carried out and (b) no
cervical cutaneous flap will be raised.
Procedure
At the time of lymphoscintigraphy, SLNs are marked on
the skin surface under scintigraphic guidance of a Co57-
labeled marker pen (held 90 to the skin surface) and
controlled transcutaneously by the nuclear medicine phy-
sician with a collimated, handheld gamma probe. Marking
the skin with the head and neck in a position as similar as
possible to the positioning during surgery may facilitate
harvesting of the sentinel node.
Following radiotracer injection and LSG, patients
undergo general anesthesia and preparation for operation.
Optionally, blue dye may be injected at this time. Transoral
excision of the primary tumor is performed either before or
after sentinel node biopsy. Prior excision reduces the
problem of shine-through from the injection site, but
potentially limits the usefulness of blue dye due to rapid
transit times through the lymphatics from the injection sites.
In the operating room, the gamma probe is covered with
sterile latex and applied transcutaneously to confirm the
accuracy of the skin markings, which may have changed
due to changes in patient positioning between LSG and
surgery.102 The theoretically optimal search pattern is to
start closest to the injection site, with the probe perpen-
dicular to the skin, using a raster pattern of 2-cm-spaced
parallel lines at right angles to the direction of the injection
site. A rise in activity is then confirmed by scanning in the
other direction. Scanning should be no faster than a few
cm/s. However, excessively slow scanning can lead to loss
of information from the change in pitch as the probe passes
over a hot node. The drop in counts as the probe is angu-
lated whilst over a hot spot can confirm location.
Location
The lymphoscintigraphy images and skin markings
guide the site of incision, which is placed along the relaxed
skin tension lines and positioned to facilitate excision of
the scar should subsequent neck dissection be required.
Sentinel nodes are reached using one or more small inci-
sions, and removed from levels I–V according to the
Robbins classification.103 Subplatysma skin flaps are not
routinely raised for biopsy-only procedures. The gamma
probe is introduced into the space along the plane of dis-
section and angled in various directions to guide the
surgeon to the sentinel node, which is then excised. Sen-
tinel nodes in the jugular chain are found close to the
internal jugular vein and those in level I will usually be
found in the submandibular triangle. If blue dye is used,
blue-stained lymphatics may be followed to the sentinel
nodes, which may be hot, blue or both. The anatomical
location of the sentinel nodes should be noted, as should its
color and radioactivity ex vivo in the operating theatre
because both blue dye and radioactivity will dissipate
before the pathological examination. In order to avoid
potential confusion, surgeons and histopathologists should
agree beforehand on the exact nomenclature used for
labeling sentinel nodes and drainage basins. Following
excision of SLNs, repeated readings are taken of the
excision bed to ensure that there are no adjacent hot nodes
that also need to be removed.36
Selection of Nodes
In OSCC, multiple SLNs are usually present, with
reported mean numbers of 1.3 to 4 (range 1–11).36 Pre-
operative LSG may underestimate the number of SLNs,
especially when multiple SLNs are in close proximity.88,104
However, the numerous other advantages of preoperative
LSG counter the suggestion that it may safely be omitted
from the procedure.88 Careful consideration of inactive
lymph nodes in the immediate vicinity of SLNs is imper-
ative. Although nonsentinel nodes should not be excised,
there may be a scenario where closely adjacent nodes are
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almost completely excised while dissecting out a sentinel
node. Although this is uncommon, the nonsentinel node
thus labeled may be sent for pathological examination.105
While preoperative imaging should detect the majority
of grossly involved nodes, clinical staging remains
imperfect.106 Any suspicious lymph nodes observed during
SNB must be excised, even in the absence of radioactivity,
since gross lymphatic involvement may block the flow of
radiotracer to these nodes. See also the section on ‘‘Mea-
sured Radioactivity.’’
SLNs are ranked according to their respective tracer
uptake ex vivo, with the SLN with the highest activity
named SLN1, that with the second highest activity SLN2,
and so forth. This does not mean that SLN2 is dependent on
SLN1, as metastases may be found in any of the multiple
SLNs independently.63,107–109
Close Spatial Relation
The problems of shine-through, whereby the high radio-
activity levels from the injection site are detected from behind
the tissue of interest, and scatter, in which the direction of
radioactivity from the injection site is changed by the tissues
and detected by the probe, are most prevalent in the sub-
mandibular and submental areas of the neck.36 For floor-of-
mouth tumors, where the distance between primary site and
SLN is smallest, this creates technical difficulty and results in
lower SLN identification rates (86%, versus 96% for other
OSCC subsites).28,110,111 Careful positioning of the gamma
probe, judicious use of malleable lead shields, and excision of
the primary tumor before SLN localization may all help to
minimize these effects.34 Another option to improve identi-
fication in level I is to perform some initial dissection below
the level of the marginal mandibular nerve, transecting the
tissues down to the level of the mylohyoid muscle. In this
manner, the lymph nodes are mobilized away from the oral
cavity, and the gamma probe placed into the newly created
tunnel and directed inferiorly away from the injection site.112
Activity Counting
Following excision, SLN radioactivity is confirmed ex
vivo using the gamma probe, and must be above back-
ground activity to be classified as hot.74 The SLN should be
placed on a surface away from the patient, or on the
upturned probe tip (facing the ceiling). Anatomic location
and radioactivity levels (cps) are recorded for all excised
nodes. All radioactive nodes should be considered SLNs
because, while there exists some confusion over the exact
definition of a SLN, it is best to err on the side of patient
safety.107 The lymphatic basin should be rechecked for
reduced radioactivity after SLN excision.113 Bed counts in
the neck after removal of SLN almost never exceed 8–10
cps (with the head of the probe slightly turned away from
the injection site).
Risk
Sentinel node biopsy is not without risks, and injuries to
the facial and spinal accessory nerves are possible through
minimal exposure. Although complications rates of less
than 1% are reported, the risk of injury to these nerves via
minimal-access incisions is theoretically higher during SNB
as compared with neck dissection. Similarly, neck dissec-
tion following positive SNB represents re-exploration in a
recently operated field, and carries with it the higher risks of
nerve or vessel damage. This reinforces the need for mini-
mal tissue injury during the initial SNB procedure.112
Experience
It is clear that experience is needed before a surgeon
starts performing sentinel node biopsy, as it carries a steep
learning curve. This has led to the recommendation of
completion of at least ten SNB-assisted elective neck dis-
sections before the procedure is performed alone.38 In
addition, it is necessary for practitioners of SNB to
understand the theoretical aspects, including handling of
radioactivity and optimal use of gamma probes.
MEASURED RADIOACTIVITY (CPS)
The role of measured cps during gamma probe detection
is unclear. Because of the narrow anatomic relationships,
defining a lower cutoff point for SLNs is practically
impossible. It has been suggested that the number of har-
vested SLNs may be limited to the three nodes with the
highest absolute cps, or the highest ratio of ex vivo node-
to-background activity (as for early studies in melanoma),
in order to reduce surgical morbidity.25,88,114–118
For correct staging, at least the three nodes with the highest
activity should be excised as SLNs, and all positive sentinels
are detected within the first five nodes of highest activity in
each patient.88,105,114 More than five SLNs are very rare, with
three-quarters of patients having B3 SLNs. For safety’s sake,
all radioactive nodes should be excised.69,105
In a study investigating the role of radioactivity in SNB,
Kovacs et al. found no significant difference in absolute cps
between positive and negative SLNs (medians of 157 and 235
cps, respectively), and the positive SLN need not have the
highest tracer accumulation (range 13–4,716 cps).36,105
Activity in SLNs was not found to correlate with administered
dose (in MBq), and the highest activity was found in level II.
The authors reported that in each patient there was one SLN
with a significantly higher cps rate than the remaining active
nodes, and this node could be found in all levels.
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Following SLN excision, the remaining lymphatic basin
is searched for residual radioactive nodes by means of an in
situ survey measurement. A count rate less than one-tenth
of the excised node with the lowest radioactivity is con-
sidered indicative that all SLNs have been identified and
removed. In some centers, lymph nodes with count rates of
less than one-tenth of the ‘‘hottest’’ excised node are not
removed. This practice is based on the results of the large
Sunbelt Melanoma trial, demonstrating a low failure rate of
2%.119 However, no similar data have yet been reported for
SCC.
The time from injection has also been found not to affect
the relative counts between SLNs, or if it does, it affects the
results only in case of very large time spans of [14 h,
depending on the half-life of the tracer used.120,121 It is
important, however, that the time span between injection
and surgery is consistent for a given study population.
As a result, the absolute radioactivity counts are less
important than relative levels between the excised nodes in
the context of SNB. Similarly, absolute radioactivity
counts cannot be compared between centers due to differ-
ences in protocol.
PATHOLOGY EVALUATION OF SENTINEL NODE
In OSCC, SNB has been examined only in the context of
relatively small observational cohort studies, and the
pathology protocols have typically been designed to detect
micrometastases (MMs) and isolated tumor cells (ITCs)
with high sensitivity. At present, the significance of finding
MMs and ITCs is unknown in OSCC. The grade of evi-
dence is currently at level III, as described in the SIGN
methodology for clinical guidelines.122 Several large-scale
validation studies (ACOSOG and the University of Miami,
SENT, the Danish national group, and the Brazilian head
and neck group) are currently underway.112,123–126
Histological Definitions
The present International Union against Cancer (UICC)
definitions are shown in Table 1.31 Whilst these definitions
have been largely accepted, little information is available
regarding the evidence on which they were based. The
relationship of these definitions to tumor–node–metastasis
(TNM) coding is demonstrated in Table 2.
One element which is clearly subjective in nature is the
assessment of cell viability, as the significance of indi-
vidual cytokeratin-positive ‘‘nonviable cells’’ is difficult to
establish. Various terms have been employed for these
cells, including ‘‘mummified cells’’ or thanatosomes.127
The present authors’ practice (K.H., P.S.) is to include such
elements in the morphological description, with careful
correlation to the adjacent hematoxylin and eosin (H&E)-
stained section. Features which may be useful include the
lack of a nucleus, but the biological potential of these cells
is as yet unknown.
In addition, the presence of cells in the lymphatic plexus
should always be recorded. Whilst their significance is
unknown, it appears that they do not represent extracap-
sular extension of tumor.
Protocol
A well-defined, written, standard operating procedure
should be established between the surgical team and the
reporting pathology laboratory. This should include how
the specimen should be delivered to the laboratory, and
outline the supporting documentation which accompanies
it and appropriate elements of radiological protection
practice. Other important elements may include agreed
turnaround times and the manner in which the results are to
be reported. An overview of the proposed pathologic
evaluation protocol is presented in Fig. 3.
Gross Sectioning
The node or nodal basin should be fixed in 10% neutral
buffered formalin (or equivalent) for 24 h, as per standard
laboratory practice. The nodes are described macroscopi-
cally, including dimensions, and excess fat is carefully
trimmed away. Nodes less than 2 mm (longest dimension)
should be processed whole, while nodes 2–5 mm should be
cut through the hilum or longest pole-to-pole diameter, and
both halves processed en face. Nodes greater than 5 mm
should be cut into 2-mm slices, longest pole to pole, with
processing of all slices en face.
Step Sectioning
A routine H&E section is prepared, and metastatic dis-
ease reported if present. If negative, six exact serial
sections are mounted, and separately numbered 1–6. Next,
150 lm material is discarded, or retained for research,
TABLE 1 UICC classification of micrometastases (MM) and iso-
lated tumor cells (ITC)
Definition Criteria
Metastasis [2 mm
Micrometastasis C0.2 mm and B2 mm
Isolated tumor cells \0.2 mm
Single cells, small clusters
No stromal reaction
No contact with vessel wall
3202 L. W. T. Alkureishi et al.
before a further six numbered serial sections are mounted.
This pattern is continued throughout the entire block. All
number 3 sections are stained by the H&E method, and
metastatic disease reported if present. If negative or
equivocal, immunocytochemistry (IHC) is performed on all
number 2 sections using a pancytokeratin antibody (see
below), and the slides examined for positivity. IHC-posi-
tive slides are compared with the adjacent section 3 H&E
slide. The remaining sections may be used if required.
Much of the published literature has utilized AE1/AE3
pancytokeratin antibody. However, concern has been
expressed regarding the specificity of this anticytokeratin
cocktail. Cross-reactivity is a problem seen with a number
of pan-cytokeratin antibodies, and may mandate the use of
more than one antibody in SNB protocols to clearly
delineate MMs and ITCs from other elements in the node,
such as dendritic cells and macrophages. However, pres-
ently it is reasonable to assume that any reputable
commercially available pancytokeratin antibody (such as
AE1/AE3 or MNF116) may be used. It is important to
recognize artifacts, and any cytokeratin-positive compo-
nents should always be compared with adjacent sections
stained by hematoxylin and eosin (Figs. 4, 5, 6, 7, 8, 9).
Microscopy
Sections should be examined using a good-quality
bright-field microscope and equivocal findings discussed
with an experienced colleague. Where pancytokeratin-
positive cells are present it is essential that adjacent sec-
tions are stained to allow morphological comparison.
Report
The side, number, and level of each node basin in the
neck must be recorded. A diagram provided by the surgical
team should be incorporated into the pathology record
where possible.
The report must include details of the numbers of nodes
found in each individual basin and which nodes were hot,
blue, both or unlabeled. The dimensions of each node must
be included and the macroscopic appearance of the gross
and cut surfaces stated.
• Macrometastasis
• Note the largest dimension of the metastatic deposit
in each node, and whether extracapsular spread is
present or not.
• Micrometastasis
• Should be recorded, even in the presence of
macrometastasis
• The largest dimension should be recorded
• Anatomical location within the node: capsular,
subcapsular, parenchymal
• Unifocal or multifocal: it is often not possible to be
confident of the exact numbers
• Presence of extracapsular spread. This is permitted
if the deposit is peripherally located and is associ-
ated with a reactive stromal response
• Isolated tumor cells (ITC)
• If evident, should be recorded, even in the presence
of macro- or micrometastasis
• If cohesive: the size of the largest deposit should be
stated
• If dispersed: note the anatomical distribution
• Benign inclusions including nevus cells, salivary
inclusions, and false-positive cytokeratin artifacts
(e.g., dendritic cells or scattered nonviable anucleate
cells) should be recorded.
TABLE 2 Comparison of UICC and TNM classifications
Generic TNM coding for sentinel nodes
pNX (sn) Sentinel lymph node could not be assessed
pN0 (sn) No sentinel node metastasis
pN1 (sn) Sentinel node metastasis
Sentinel nodes with micrometastasis only are identified by (mi)
pN1 (sn) (mi) single ipsilateral node with micrometastasis
pN2 (sn) (mi) multiple ipsilateral nodes with micrometastasis
Sentinel nodes with isolated tumor cells are coded separately for morphological and nonmorphological techniques such as PCR or flow
cytometry
pN0 (i-)(sn) No sentinel lymph node metastasis histologically, negative morphological findings for isolated tumor cells (ITC)
pN0 (i?)(sn) No sentinel lymph node metastasis histologically, positive morphological findings for isolated tumor cells (ITC)
pN0 (mol-)(sn) No sentinel lymph node metastasis histologically, negative nonmorphological findings for isolated tumor cells (ITC)
pN0 (mol?)(sn) No sentinel lymph node metastasis histologically, positive nonmorphological findings for isolated tumor cells (ITC)
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The histopathological features of ITCs need careful
description, as the UICC size cutoff by necessity encom-
passes small metastases which vary greatly in size and
presumably in biological potential. Positive findings using
nonmorphological methods in the absence of histologically
proven metastasis are generally considered as ITCs.
Other Methodologies
Frozen Sections The use of frozen-section evaluation for
SLNs has been described in a number of recent reports, and
the results appear promising, with negative predictive
values ranging from 83% to 99%.64,128,129 These results are
in contrast to an earlier report by Civantos et al., who
described poor sensitivity of frozen section compared with
step-serial sectioning in a series of 43 oral cancer
patients.130 The main advantage of the technique is that it
may allow a majority of patients to undergo a single-stage
procedure. While the use of frozen section is advocated by
some authors, it has not yet gained universal acceptance.
Imprint Cytology
The use of imprint cytology in conjunction with frozen
sections in the assessment of SLNs has been described in
other tumors such as breast adenocarcinoma. One study in
OSCC based on 30 cases demonstrated high sensitivity and
specificity, though a recent study showed frozen section to
FIG. 3 Pathology evaluation of sentinel lymph nodes
FIG. 4 Isolated tumor cells stained by AE1/AE3 in a sentinel lymph
node
FIG. 5 A micrometastasis found in the seventh level of a sentinel
node that was clear on initial sectioning. Viable nucleated squamous
cells are present in a cohesive group. Section quality is suboptimal
and recutting is not possible
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be a more accurate method of intraoperative diagno-
sis.128,131 Imprint cytology has an advantage over frozen
section in that no tissue is lost in the generation of the
sample, however much larger studies are required before
considering adoption into the protocol.
Reverse-Transcriptase Polymerase Chain Reaction (RT-
PCR) Methods with increased sensitivity, such as
cytokeratin RT-PCR, have been suggested. The small
number of studies published demonstrate expression of
cytokeratins in nodes which were metastasis negative on
initial assessment. However, only a proportion of the nodes
demonstrated metastases on serial sectioning.132,133 The
clinical role of these methods in the future remains
uncertain given the ongoing concerns regarding their
specificity together with the associated medicolegal
problems, given that significant tissue must be used
which has not been assessed histopathologically.
Burden of Work
The authors recognize that, on average, 2.5 sentinel
node basins are yielded per neck side. The protocol above
may produce up to 12 levels per node. If three nodes are
present in each basin there could be 180 slides to examine.
On the other hand, the majority of sentinel nodes are small
and the nodes from a single basin can often be grouped into
one cassette (using ink to identify ‘‘hot’’ and ‘‘blue’’
nodes), saving laboratory time and effort. In addition, the
described protocol has the ability to detect all MMs.
FIG. 6 Cytokeratin-positive cells in a sentinel node stained by CKC
pan cytokeratin. The white arrow shows a contaminant squame (this
can be ascertained by the geometric outline, lack of nucleus, and by
focusing at high power). The black arrows show nonnucleated
individual tumor cells, and dendritic cells can be seen in the
background
FIG. 7 A group of nucleated isolated tumor cells stained by AE1/
AE3 in a sentinel node
FIG. 8 Multinucleated and mononuclear macrophages revealed by
the detailed protocol in a sentinel node that was clear in the first
sections. These were suspicious for ITCs within the island
FIG. 9 Adjacent field to Fig. 5 stained by AE1/AE3, showing
absence of tumor cells
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According to Cochran’s principle, metastatic deposits
tend to cluster in the plane of the hilum, and some authors
argue the case for examination of bisected sentinel nodes at
three or six levels only.134 Although such a protocol can
theoretically miss a MM, it may turn out that no useful
information is added by leveling through the block beyond
six levels.135 However, several studies report that addi-
tional sentinel nodes are upstaged by step-serial sectioning
with cytokeratin immunohistochemistry, compared with
H&E only.82
OUTCOME ANALYSIS
The success of this multidisciplinary staging technique
depends on good communication between all of the indi-
vidual components; imaging, surgery, and histopathology.
The multidisciplinary team (MDT) setting should be uti-
lized for the discussion of every patient, and regular audit
of patient outcomes against published data should be car-
ried out. SLNs should be successfully located and
harvested in [90% patients.28 The accuracy of the tech-
nique can be assessed by the proportions of patients whose
SLN contain metastases, which should match that of END
(20–30%, depending on patient population and tumor
size).136 Lastly, the rate of false negatives (SLN-negative
patients who develop early recurrent disease) should be
\5%.137
Further studies are required to determine the full clinical
significance of micrometastasis and individual tumor cells
in OSCC. The biological potential of the tumor cells may
vary with differing types of tumors, and clinical decisions
currently have to be made on the basis of grade, stage, and
margin status of the primary lesion as well as on micro-
scopic findings in the sentinel node.138,139 The optimum
protocol will hopefully emerge from the large-scale trials
and studies currently in progress.110,123–126 One of the
major aims of SNB in OSCC is to achieve better staging,
and thorough pathological examination of SLNs remains
the standard.
SUMMARY
Successful application of the SNB technique is depen-
dent on good communication between all members of the
multidisciplinary team, and this joint guideline represents
an extension of that approach. Sentinel node biopsy pro-
vides an additional tool for staging patients with early
OSCC. However, it is not without limitations, and all
practitioners of SNB must be aware of these. It is hoped
that this document will serve as a reference outlining the
optimal practice for the provision of SNB in patients with
OSCC, based on the best currently available evidence. As
such, the use of the above protocol is recommended until
further data, in the form of results from currently underway
large prospective studies, become available.
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